Explore the Agenda

8:00 am Check In & Registration

8:45 am Chair’s Opening Remarks

Enhancing Conjugation Chemistry for Unlocking Synergistic Potential In Dual Payload ADCs

9:00 am Next-Generation Multi-Payload ADCs: How Site-Selective Conjugations Enable New Modalities

CEO, Catena Biosciences
  • Potential of dual-payload ADCs and challenges presented by traditional conjugation approaches
  • Review of approaches to manufacturing dual-payload ADCs, with focus on the CysTyr platform for site-specific conjugation
  • Efficacy of Multi-Payload Conjugates produced using CysTyr conjugation

9:30 am Accelerating ADC Development and Manufacturing with ThioBridge™ Conjugation and Linker Technology

Senior Director of Chemistry, Abzena
  • ThioBridgeTM conjugation technology insights; how the technology works, and its advantages over stochastic conjugation technologies.
  • Modulation of Drug-Antibody Ratio (DAR) using ThioBridge as effective feature to optimize therapeutic activity.
  • In vitro and in vivo stability of ADCs generated using ThioBridgeTM
  • Optimization of linker architecture to enhance in vivo efficacy of ThioBridgeTM ADCs. In vivo data for relevant ADCs generated using ThioBridgeTM technology
  • ThioBridgeTM linker-payload and ADC manufacturing considerations.

10:00 am Morning Break & Speed Networking

11:00 am Designing Branched Linkers for Dual Payload ADCs to Balance Synergy & Selectivity

Director, Chemistry, Araris Bio
  • Investigating chemical engineering strategies for designing branch linkers for achieving distinct tumor-specific cleavage mechanisms
  • Addressing challenges in maintaining payload stability and ensuring effective payload release while preserving the overall functionality of the ADC
  • Exploring the use of modified conjugation methods to achieve controlled ratios of each payload, ensuring synergistic effects without compromising safety or efficacy

11:30 am Targeting Solid Tumors & Hematological Malignancies with ADCs Utilizing Auristatin, Topo1i & Dual Payloads

Chief Executive Officer, Glykos
  • Hydrophilic linker with optimized cleavable moiety enables efficient auristatin, exatecan / topoisomerase 1 and novel modality linker-payloads for ADC generation
  • DAR4 and DAR8 MMAU auristatin ADCs showed outstanding therapeutic window against solid tumors and hematological malignancies
  • Utilizing optimized linker and conjugation technologies for dual-payload ADCs

12:00 pm Lunch

Advancing Linker Design Strategies for Achieving the Optimal Stability Profile

1:00 pm Exploring the Linkers & Architectures of Bicycle® Constructs

Associate Director - Chemistry, Bicycle Therapeutics plc
  • Bicyclic peptides (Bicycles®) as a new targeting modality
  • Differences between Bicycles-Conjugates and Antibody-Conjugates
  • Linkers, conjugations and architectures of Bicycle constructs

1:30 pm The Story of the B7-H7 Targeting ADC: Exploring a Proprietary Linker for Maximal Compatibility with Targeting Biology

Chief Scientific Officer, NextPoint Therapeutics
  • Attributes of B7-H7 as a tumor target
  • ADC linker approach for addressing the vast B7-H7 positive patient population
  • NPX125 linker design and attributes

2:00 pm The Impact of Site-Specific Light Chain Conjugation on Antibody Structure Using Hydrogen Exchange-Mass Spectrometry (HX-MS)

Postdoctoral Researcher, University of Kansas
  • Differential HX-MS was used to explore the impact of drug conjugation on the conformational stability and structural dynamics of a mAb
  • A side-by-side comparison between a mAb conjugated with a pyrrolobenzodiazepine drug and an unconjuagated mAb revealed subtle conformational changes induced by the linker-drug particularly near the site of conjugation
  • To gain a comprehensive understanding of these effects other complementary biophysical techniques (DSC, DSF, SEC, and icIEF) were integrated into the study

2:30 pm Afternoon Break

3:00 pm Exploring Click-Cleavable ADCs & Their Application Scope

Chief Scientific Officer, Tagworks
  • Understanding limitations of current ADC linkers
  • Exploring the principle and design of click-cleavable ADC linkers
  • Targeting scope expansion and potential for improved efficacy and safety offered by click-cleavable ADCs

3:30 pm Novel: Exatecan-based ADC Using HDP’s Innovative Multimeric Linker Platform

Group Leader Chemistry, Heidelberg Pharma
  • A new multimeric linker platform facilitated the development of HDP-201, an ADC with exatecan as payload, as novel therapeutic modality for the treatment of solid tumors
  • The role of solubility enhancers in enabling site-specific coupling to cysteines, leading to stable, potent, and well tolerated ADCs
  • HDP-201 shows dose-dependent tumor regression in vivo and enhanced anti-tumor efficacy following multiple doses

4:00 pm A Clickable Antibody Design to Generate Antibody-Drug Conjugates (ADCs) in a Trojan Horse Manner

Researcher, IQS Barcelona
  • Conjugation within the Fab cavity strongly reduces ADC hydrophobicity 
  • Conjugation within the Fab cavity does not compromise conjugation efficiency nor functionality
  • Linker length matters within the Fab cavity

4:30 pm End of Scientific Program Day One